bismuth-212

Bismuth-212 is an **alpha-particle emitting radionuclide** used as a payload for targeted alpha radiotherapy. It is a short-lived radioisotope of bismuth with a half-life of about 60 minutes, typically obtained from a lead-212 generator system and then attached to targeting carriers such as monoclonal antibodies, albumin particles, or nanoparticles through chelators including DOTA or DTPA. Its therapeutic effect is mediated by high linear energy transfer alpha emissions that produce highly localized, largely irreparable DNA damage in nearby cells, making it most suitable for small-volume tumors, hematologic malignancies, and micrometastatic disease rather than as a standalone conventional drug product. Development has largely been preclinical and investigator-driven across oncology settings including leukemia, breast cancer, and other solid tumors, with no clearly established single commercial brand or developer for unconjugated bismuth-212 itself.

Other names

radiobismuth-212radiobismuth212radiobismuth 212bismuth-212 radioisotopebismuth212 radioisotopebismuth 212 radioisotope